Aeterna Zentaris
AEZS
#10198
Rank
S$22.69 M
Marketcap
S$7.41
Share price
2.14%
Change (1 day)
N/A
Change (1 year)

Revenue for Aeterna Zentaris (AEZS)

Revenue in 2024 (TTM): S$8.53 Million

According to Aeterna Zentaris's latest financial reports the company's current revenue (TTM ) is S$8.19 Million. In 2023 the company made a revenue of S$7.16 Million a decrease over the revenue in the year 2022 that were of S$14.98 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Aeterna Zentaris from 1997 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) S$8.53 M19.04%
2023 S$7.16 M-52.18%
2022 S$14.98 M2.42%
2021 S$14.63 M28.11%
2020 S$11.42 M13.25%
2019 S$10.08 M14.96%
2018 S$8.77 M-15.93%
2017 S$10.43 M-8.06%
2016 S$11.35 M33.28%
2015 S$8.51 M-8.13%
2014 S$9.27 M23.64%
2013 S$7.49 M19.52%
2012 S$6.27 M-17.42%
2011 S$7.59 M8.07%
2010 S$7.02 M48.38%
2009 S$4.73 M-2.05%
2008 S$4.83 M8.26%
2007 S$4.46 M18.18%
2006 S$3.78 M21.05%
2005 S$3.12 M55.75%
2004 S$2 M-5.88%
2003 S$2.13 M94.7%
2002 S$1.09 M26.89%
2001 S$0.86 M36.59%
2000 S$0.63 M64.16%
1999 S$0.38 M-15.7%
1998 S$0.45 M-77.52%
1997 S$2.02 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Spectrum Pharmaceuticals
SPPI
S$33.34 M 307.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
S$73.05 B 891,831.82%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Bristol-Myers Squibb
BMY
S$62.24 B 759,905.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
S$61.58 B 751,853.67%๐Ÿ‡ซ๐Ÿ‡ท France
Halozyme Therapeutics
HALO
S$1.61 B 19,564.71%๐Ÿ‡บ๐Ÿ‡ธ USA